B41 Paracoccidioidomycosis

Name of the Condition

• Paracoccidioidomycosis

Summary

Paracoccidioidomycosis is a systemic fungal infection caused by Paracoccidioides brasiliensis or Paracoccidioides lutzii. It primarily affects the lungs but can disseminate to other organs, including the skin, mucous membranes, and lymph nodes. The condition is endemic to certain regions of Latin America and is characterized by a chronic or subacute course, with symptoms ranging from mild respiratory issues to severe systemic disease.

Causes

The infection is caused by inhaling fungal spores from the environment, typically found in soil or decaying organic matter. The fungi enter the respiratory tract and may remain localized or spread hematogenously to other tissues. The disease is not transmitted person-to-person.

Risk Factors

• Residence or travel to endemic areas (e.g., parts of Brazil, Colombia, Venezuela).
• Occupational exposure to soil or agricultural activities.
• Immunocompromised states, such as HIV/AIDS, diabetes, or chronic steroid use.
• Male gender, as the disease is more prevalent in men.
• Smoking or chronic lung disease.

Symptoms

• Chronic cough, chest pain, or shortness of breath.
• Weight loss, fever, or night sweats.
• Skin lesions (ulcers, nodules) or mucosal involvement (oral, nasal, or laryngeal ulcers).
• Lymph node enlargement, particularly in the neck or groin.

Diagnosis

Diagnosis is confirmed by identifying the fungus in clinical specimens (e.g., sputum, tissue biopsies) via microscopy, culture, or molecular testing. Imaging (e.g., chest X-ray or CT) may show pulmonary infiltrates or nodules. Serological tests (e.g., antibody detection) can support the diagnosis but are not definitive.

Treatment Options

Antifungal therapy is the mainstay of treatment, typically with azoles (e.g., itraconazole) or amphotericin B for severe cases. Treatment duration varies based on disease severity and response, often lasting 6–12 months or longer. Supportive care may address respiratory or systemic symptoms.

Prognosis and Follow-Up

With appropriate treatment, most patients recover, though relapse can occur. Severe or disseminated disease may have a guarded prognosis, especially in immunocompromised individuals. Follow-up includes monitoring for treatment response, symptom recurrence, and potential organ damage.

Complications

• Respiratory failure from extensive lung involvement.
• Disseminated infection affecting the central nervous system, liver, or adrenal glands.
• Chronic lung disease or fibrosis.
• Secondary bacterial infections.

Lifestyle & Prevention

• Avoiding activities that disturb soil in endemic areas (e.g., excavation) may reduce exposure risk.
• Using protective equipment (e.g., masks) during high-risk activities.
• Early diagnosis and treatment of underlying immunosuppressive conditions.

When to Seek Professional Help

Seek care if experiencing persistent respiratory symptoms, unexplained weight loss, or skin/mucosal lesions, especially after travel to endemic regions. Prompt evaluation is critical for immunocompromised individuals.

Tips for Medical Coders

• Code B41 is used for paracoccidioidomycosis, regardless of site or severity.
• Document the clinical context (e.g., pulmonary, disseminated) to support coding accuracy.
• Ensure differentiation from other fungal infections (e.g., histoplasmosis) when applicable.